KOS-953: Interim Phase Ib data

In an ongoing, dose-escalation Phase Ib trial in 21 evaluable patients IV KOS-953 plus Velcade bortezomib was well tolerated with no pharmacokinetic interactions between the 2 treatments. Of the 6 Ve...